Quantcast
Last updated on April 21, 2014 at 9:22 EDT

Latest Boehringer Ingelheim Stories

2013-11-06 12:29:04

New line features an updated equine influenza strain to provide most relevant respiratory protection to horses. ST. JOSEPH, Mo., Nov. 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Vetmedica, Inc. (BIVI), introduces the new Vetera(®) XP line of vaccines, the only vaccine line that contains the most relevant strains of equine influenza virus (EIV) that affect horses today. (Logo: http://photos.prnewswire.com/prnh/20120925/CG80722LOGO) By protecting horses against Richmond/07,...

2013-11-05 23:01:35

The Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company are title sponsors. Brownsville, TX (PRWEB) November 05, 2013 On Saturday, November 9, 2013, the Brownsville Community Health Center (BCHC) will present its third annual family health and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. The event promotes Hispanic family physical activity and good nutrition for better...

2013-11-02 08:21:34

Multiple studies presented at The Liver Meeting® investigating faldaprevir include difficult-to-cure patient populations, such as those with HIV/HCV coinfection and advanced liver disease RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data from its Phase 3 clinical trial program, STARTVerso(TM), which evaluates the investigational protease inhibitor, faldaprevir, in combination with pegylated interferon and ribavirin...

2013-11-02 08:21:30

Clinical trial studies an all-oral, 12-week regimen containing the investigational compounds faldaprevir, deleobuvir, and Presidio Pharmaceuticals' PPI-668 with and without ribavirin in 36 difficult-to-treat genotype-1a HCV patients RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim data from its Phase 2a hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals, Inc. that showed all patients (13/13)...

2013-10-31 23:31:05

MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: Type 2 Diabetes Market to 2019 http://www.marketresearch.com/land/product.asp?productid=7840706&progid=85831. Rockville, MD (PRWEB) October 31, 2013 Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 The global type 2 diabetes market is expected to grow from $20.4 billion in 2012...

2013-10-31 12:27:18

ST. JOSEPH, Mo., Oct. 31, 2013 /PRNewswire/ -- As the holiday season approaches more and more dogs will be boarding at veterinary clinics boarding facilities or pet resorts, or traveling with other dogs or visiting family and friends with dogs. This increased interaction outside of the home puts those dogs at risk for Canine Infectious Respiratory Disease (CIRD), or kennel cough, a highly contagious respiratory disease. The disease is spread by air and by dogs in close contact with...

2013-10-28 23:00:50

The Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Are Title Sponsor Houston, TX (PRWEB) October 28, 2013 On Saturday, November 2, 2013, the Hispanic Health Coalition will present its seventh annual family health and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. The event promotes Hispanic family physical activity and good nutrition for better health and wellness for...

2013-10-23 08:29:12

Boehringer Ingelheim makes significant investment in groundbreaking hepatitis C program with two leading researchers from the Francis Family Liver Clinic, Toronto Western Hospital University Health Network BURLINGTON, ON, Oct. 23, 2013 /CNW/ - In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network (UHN), together with Boehringer Ingelheim (Canada) Ltd. (BICL), announced today a multi-year partnership that aims to improve care,...

2013-10-22 23:01:43

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company are Title Sponsor. Over 25,000 are expected at community events celebrating culture and supporting families in making good nutrition and movement a daily part of life. Washington, D.C. (PRWEB) October 22, 2013 Today, the National Alliance for Hispanic Health (the Alliance) announced a new sponsorship with Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly). BIPI and Lilly are bringing...

2013-10-22 08:33:08

UPPSALA, Sweden, October 18, 2013 /PRNewswire/ -- Beactica today announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim. Financial terms of the agreement were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20121029/572724 ) "We...